Data Sheet (Cat.No.T21444)

TargetMol
A DRUG SCREENING EXPERT

Diphencyprone

Chemical Properties

CAS No.:	886-38-4
Formula:	C15H10O
Molecular Weight:	206.24
Appearance:	N/A
Storage:	0-4℃ for short term (days to weeks), or -20℃ for long term (months).

Biological Description

Description	Diphencyprone is a topically administered drug intended for the treatment of alopecia areata and alopecia totalis. It acts as a local irritant, triggering a local sensitization. It triggers an immune response that opposes the action of the autoreactive cells that otherwise cause hair loss.

Solubility Information

Solubility	Water: Insoluble DMSO: Soluble (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.849 mL	24.244 mL	48.487 mL
5 mM	0.970 mL	4.849 mL	9.697 mL
10 mM	0.485 mL	2.424 mL	4.849 mL
50 mM	0.097 mL	0.485 mL	0.970 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 ℃ for 6 months; - 20 ℃ for 1 month. Please use it as soon as possible.

Reference

1. Gulati N, Carvajal RD, Postow MA, Wolchok JD, Krueger JG. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. Exp Dermatol. 2016 Apr 8. doi: 10.1111/exd.13030. [Epub ahead of print] PubMed PMID: 27061281.

2. Lamb RC, Young D, Holmes S. Retrospective review of diphencyprone in the treatment of alopecia areata. Clin Exp Dermatol. 2015 Dec 1. doi: 10.1111/ced.12776. [Epub ahead of print] PubMed PMID: 26620737.

3. Moncrieff M, Fadhil M, Garioch J. Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases (LIMMs) of the skin. The 5-Year Norwich experience. Br J Dermatol. 2015 Nov 24. doi: 10.1111/bjd.14314. [Epub ahead of print] PubMed PMID: 26598951.

4. Bulock KG, Cardia JP, Pavco PA, Levis WR. Diphencyprone Treatment of Alopecia Areata: Postulated Mechanism of Action and Prospects for Therapeutic Synergy with RNA Interference. J Investig Dermatol Symp Proc. 2015 Nov;17(2):16-8. doi: 10.1038/jidsymp.2015.33. PubMed PMID: 26551938.

Inhibitors · Natural Compounds · Compound Libraries

Tel:781-999-4286 E-mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481